Sarepta Will Present Duchenne Study Data in September
The company will share Phase 4 findings on its gene therapy, delandistrogene moxeparvovec, at a scientific conference.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies are transparent about the safety risks of new gene therapies?
Sarepta Therapeutics is set to present seven posters on its neuromuscular portfolio at the 27th Annual Neuromuscular Study Group Scientific Meeting, running from September 25-27, 2026. The research includes data from the prospective, multi-center Phase 4 ENDURE study involving patients with Duchenne muscular dystrophy.
Why it matters
The company aims to provide insight into the real-world application of its gene therapy, particularly regarding safety profiles in patients undergoing prophylactic immunosuppression. These findings contribute to the ongoing clinical understanding of gene therapy delivery and patient management in neuromuscular care.
The presentations focus on the Phase 4 ENDURE study, an observational analysis of patients receiving delandistrogene moxeparvovec. This dataset includes safety performance for patients concurrently receiving sirolimus, a medication used to prevent organ transplant rejection, as a prophylactic immunosuppressant.
The players
Sarepta Therapeutics
A biotechnology firm focused on precision genetic medicine, specifically developing RNA-targeted therapeutics and gene therapies for rare neuromuscular diseases.
The details
The ENDURE study evaluates delandistrogene moxeparvovec, a gene therapy designed to treat Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle degeneration. The researchers analyze the integration of prophylactic immunosuppression with sirolimus, which acts as a mammalian target of rapamycin (mTOR) inhibitor to modulate the immune response during treatment. These posters describe results from this prospective, multi-center observational effort.
Timeline
September 25-27, 2026: The 27th Annual Neuromuscular Study Group Scientific Meeting takes place.
September 25, 2026: Poster sessions occur between 6:00 PM and 8:00 PM EST.
The Tech Race
The data presentation at the 27th Annual Neuromuscular Study Group Scientific Meeting follows the standard academic process for validating gene therapy outcomes in real-world settings. This effort allows researchers to contextualize results against broader longitudinal registries and competing gene delivery platforms.
This research provides clinical evidence for healthcare providers regarding the real-world safety of managing Duchenne muscular dystrophy patients with sirolimus during gene therapy. Physicians and families tracking treatment protocols should monitor the published posters to understand the safety implications for current care standards.
The takeaway
The study offers a window into the safety profile of combined gene therapy and immunosuppression protocols in clinical practice. Observers should monitor the post-meeting release of these seven posters for details on longitudinal safety markers and patient outcomes.
What happens next
Following the conclusion of the meeting, abstracts and presentation materials will be released on the Sarepta Therapeutics website once the embargo is lifted.
Further reading
For broader context on current clinical advancements, explore the latest research in /Biotech.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical companies are transparent about the safety risks of new gene therapies?
